Currently, there are 46.10M common shares owned by the public and among those 39.62M shares have been available to trade.
The company’s stock has a 5-day price change of 63.23% and 8.67% over the past three months. URGN shares are trading 12.96% year to date (YTD), with the 12-month market performance down to -8.10% lower. It has a 12-month low price of $3.42 and touched a high of $20.70 over the same period. URGN has an average intraday trading volume of 2.05 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 95.29%, 38.63%, and 10.22% respectively.
Institutional ownership of UroGen Pharma Ltd (NASDAQ: URGN) shares accounts for 91.87% of the company’s 46.10M shares outstanding.
It has a market capitalization of $554.67M and a beta (3y monthly) value of 0.53. The earnings-per-share (ttm) stands at -$3.18. Price movements for the stock have been influenced by the stock’s volatility, which stands at 19.11% over the week and 20.45% over the month.
Analysts forecast that UroGen Pharma Ltd (URGN) will achieve an EPS of -0.81 for the current quarter, -0.56 for the next quarter and -0.87 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.94 while analysts give the company a high EPS estimate of -0.94. Comparatively, EPS for the current quarter was -0.91 a year ago. Earnings per share for the fiscal year are expected to increase by 4.92%, and 60.39% over the next financial year.
Scotiabank coverage for the UroGen Pharma Ltd (URGN) stock in a research note released on April 16, 2025 offered a Sector Outperform rating with a price target of $23. Ladenburg Thalmann was of a view on February 19, 2025 that the stock is Buy, while Guggenheim gave the stock Buy rating on August 22, 2024, issuing a price target of $40. Jefferies on their part issued Hold rating on February 08, 2023.
